Sareum Holdings plc (LSE:SAR) said on 8 October 2026 that it intends to raise newShare Capitalusing the Capital Access Window, a mechanism introduced through updates to the AIM Rules for Companies announced in August 2026. The company referred to the transaction as the "Proposed …
MedPal AI plc (LSE:MPAL), quoted on AIM and in Frankfurt, issued a trading update on 8 October 2026. On Monday 5 October 2026, its New HealthBusinessdispensed more than 2,300 prescription orders in one day, with a total order value of about £0.3m.
In an announcement dated 8 October 2026, Futura Medical (LSE:FUM) said Angela Hildreth will step down as Finance Director and Chief Operating Officer to pursue other opportunities. Her departure from the executive role takes effect on 13 November 2026, following what the company described …
CVS Group (LSE:CVSG), the FTSE 250 veterinary services provider, has gained greater clarity on its regulatory landscape. Final results published on 24 September came just two days after the Competition and Markets Authority published its final remedies order following its market investigation into the …
The fall followed one of the strongest runs in the FTSE 250 this year. The shares roughly doubled from lows around 107p in July. In late September, LSE:ONT climbed from about 182p to more than 217p over two sessions, and trading volumes spiked to …
As a FTSE All-Share constituent with a focus on smaller, more innovative companies, LSE:BIOG tends to move more sharply than the broader healthcare sector. Thursday's fall reflected a combination of policy news, rate fears and weakness in US biotech shares.
The trust is a constituent of the FTSE All-Share index. Its lead managers are James Douglas and Gareth Powell of Polar Capital.
The trust is a constituent of the FTSE 250 index. Its portfolio is managed by OrbiMed, led by Sven Borho and Trevor Polischuk, while FrostrowCapitalacts as company secretary.
Verici Dx — LSE:VRCI — is in focus after the latest corporate development: Proposed placing puts funding and dilution at the centre of the story. The company is traded on the London Stock Exchange’s AIM market, rather than being a constituent of the FTSE …
Arecor Therapeutics — LSE:AREC — is in focus after the latest corporate development: Half-year results presentation puts pipeline and cash runway under scrutiny. The company is traded on the London Stock Exchange’s AIM market, rather than being a constituent of the FTSE 100 or …